Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo
Krishan Kumar, … , Kazumi Ebine, Hidayatullah G. Munshi
Krishan Kumar, … , Kazumi Ebine, Hidayatullah G. Munshi
Published February 9, 2017
Citation Information: JCI Insight. 2017;2(3):e88032. https://doi.org/10.1172/jci.insight.88032.
View: Text | PDF
Research Article Gastroenterology Oncology

BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo

  • Text
  • PDF
Abstract

The fibrotic reaction, which can account for over 70%–80% of the tumor mass, is a characteristic feature of human pancreatic ductal adenocarcinoma (PDAC) tumors. It is associated with activation and proliferation of pancreatic stellate cells (PSCs), which are key regulators of collagen I production and fibrosis in vivo. In this report, we show that members of the bromodomain and extraterminal (BET) family of proteins are expressed in primary PSCs isolated from human PDAC tumors, with BRD4 positively regulating, and BRD2 and BRD3 negatively regulating, collagen I expression in primary cancer-associated PSCs. We show that the inhibitory effect of pan-BET inhibitors on collagen I expression in primary cancer-associated PSCs is through blocking of BRD4 function. Importantly, we show that FOSL1 is repressed by BRD4 in primary cancer-associated PSCs and negatively regulates collagen I expression. While BET inhibitors do not affect viability or induce PSC apoptosis or senescence, BET inhibitors induce primary cancer-associated PSCs to become quiescent. Finally, we show that BET inhibitors attenuate stellate cell activation, fibrosis, and collagen I production in the EL-KrasG12D transgenic mouse model of pancreatic tumorigenesis. Our results demonstrate that BET inhibitors regulate fibrosis by modulating the activation and function of cancer-associated PSCs.

Authors

Krishan Kumar, Brian T. DeCant, Paul J. Grippo, Rosa F. Hwang, David J. Bentrem, Kazumi Ebine, Hidayatullah G. Munshi

×

Figure 8

BET inhibitors decrease fibrosis and collagen production in the EL-KrasG12D mouse model of pancreatic tumorigenesis.

Options: View larger image (or click on image) Download as PowerPoint
BET inhibitors decrease fibrosis and collagen production in the EL-KrasG...
Two-month-old EL-KrasG12D mice, which express mutant Kras in the acinar cells, were i.p. injected with JQ1 (50 mg/kg body weight, n = 13) or vehicle control [DMSO/(2-hydroxypropyl)-β-cyclodextrin, n = 9] daily for 5 days per week for 4 weeks. (A) The pancreatic tissue sections were stained with H&E to observe phenotypic changes and additionally stained for the ductal marker CK19 together with DAPI to counterstain the nuclei. (B) The pancreatic sections were trichrome stained (blue = fibrosis) to assess for fibrosis. The pancreatic sections were also stained for α-SMA to evaluate for stellate cell activation and costained for BRD4. (C) The sections were stained for collagen I expression, and the nuclei were costained with DAPI. (D) The extent of ADM and fibrosis, and the relative expression of α-SMA and collagen I were quantified as described in Methods. *P < 0.05, ***P < 0.001. Data were analyzed by 2-tailed unpaired Student’s t test. Scale bars: 50 μm. ADM, acinar-to-ductal metaplasia; α-SMA, α–smooth muscle actin; BET, bromodomain and extraterminal; CK19, cytokeratin 19.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts